Matinas Biopharma

Matinas Biopharma company information, Employees & Contact Information

Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas’ LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.

Company Details

Employees
17
Founded
-
Address
1545 Route 206, Suite 302, Bedminster,new Jersey 07921,united States
Phone
1(908) 443-1860
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Manager jobs.
HQ
Bedminster, New Jersey
Looking for a particular Matinas Biopharma employee's phone or email?

Matinas Biopharma Questions

News

Matinas BioPharma Announces Agreement for the Acquisition - GlobeNewswire

Matinas BioPharma Announces Agreement for the Acquisition GlobeNewswire

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction - Yahoo Finance

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction Yahoo Finance

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution - Stock Titan

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution Stock Titan

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update - Yahoo Finance

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update Yahoo Finance

Oral Amphotericin B Formulation Gets Orphan Drug Status for Cryptococcosis - Medical Professionals Reference

Oral Amphotericin B Formulation Gets Orphan Drug Status for Cryptococcosis Medical Professionals Reference

MTNB Stock Price and Chart — AMEX:MTNB - TradingView

MTNB Stock Price and Chart — AMEX:MTNB TradingView

Matinas BioPharma Announces Publication of Results from the - GlobeNewswire

Matinas BioPharma Announces Publication of Results from the GlobeNewswire

Top Matinas Biopharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant